Chongqing Huazhi Biopharmaceutical

Chongqing Huazhi Biopharmaceutical is a clinical-stage biotechnology company headquartered in Chongqing, China, dedicated to the discovery and development of innovative small molecule drugs. The company focuses on therapeutic areas with significant unmet needs, including metabolic diseases, oncology, and autoimmune disorders. Its lead program, HZ-A-018, is a highly selective URAT1 inhibitor being developed for the treatment of hyperuricemia and gout. Huazhi Biopharmaceutical aims to provide high-quality, affordable innovative medicines through its integrated R&D platform and strategic collaborations. The company leverages its internal expertise in medicinal chemistry and pharmacology to advance its pipeline from discovery through clinical proof-of-concept.